Adaptive Biotechnologies Corp(ADPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADPT Adaptive Biotechnologies Corp

Closed 05-15 16:00:00 EDT

12.83

-0.35

-2.66%

盘后13.08

+0.25+1.95%

18:36 EDT

High13.15	Low12.81	Vol1.56M
Open12.93	D1 Closing13.18	Amplitude2.58%
Mkt Cap2.05B	Tradable Cap1.51B	Total Shares159.76M
T/O20.24M	T/O Rate1.33%	Tradable Shares117.37M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADPT","market":"US","secType":"STK","nameCN":"Adaptive Biotechnologies Corp","latestPrice":12.83,"timestamp":1778875200000,"preClose":13.18,"halted":0,"volume":1563597,"hourTrading":{"tag":"盘后","latestPrice":13.08,"preClose":12.83,"latestTime":"18:36 EDT","volume":43970,"amount":564176.62,"timestamp":1778884598858,"change":0.25,"changeRate":0.019486,"amplitude":0.019486},"delay":0,"changeRate":-0.0265553869499241,"floatShares":117369033,"shares":159760700,"eps":-0.325352,"marketStatus":"Closed","change":-0.35,"latestTime":"05-15 16:00:00 EDT","open":12.93,"high":13.15,"low":12.81,"amount":20241072.757206,"amplitude":0.025797,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.325352,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779091200000},"marketStatusCode":5,"adr":0,"listingDate":1561608000000,"exchange":"NASDAQ","adjPreClose":13.18,"preHourTrading":{"tag":"盘前","latestPrice":12.91,"preClose":13.18,"latestTime":"04:00 EDT","volume":7,"amount":90.5807,"timestamp":1778832028076,"change":-0.27,"changeRate":-0.020486,"amplitude":0.015986},"postHourTrading":{"tag":"盘后","latestPrice":13.08,"preClose":12.83,"latestTime":"18:36 EDT","volume":43970,"amount":564176.62,"timestamp":1778884598858,"change":0.25,"changeRate":0.019486,"amplitude":0.019486},"volumeRatio":1.093907,"impliedVol":0.6487,"impliedVolPercentile":0.247},"requestUrl":"/m/hq/s/ADPT","defaultTab":"news","newsList":[{"id":"2635246943","title":"Adaptive Biotechnologies Is Maintained at Equal-Weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2635246943","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635246943?lang=en_us&edition=fundamental","pubTime":"2026-05-13 00:31","pubTimestamp":1778603460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADPT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 12:31 ET (16:31 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634290451","title":"Morgan Stanley Lowers Price Target on Adaptive Biotechnologies to $18 From $21, Keeps Equalweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2634290451","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634290451?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:39","pubTimestamp":1778582374,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies (ADPT) has an average rating of buy and mean price target of $20.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634242848","title":"A Look At Adaptive Biotechnologies (ADPT) Valuation After Strong Q1 MRD Growth And Raised Full Year Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2634242848","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634242848?lang=en_us&edition=fundamental","pubTime":"2026-05-10 22:30","pubTimestamp":1778423434,"startTime":"0","endTime":"0","summary":"First quarter MRD momentum and guidance raise\nAdaptive Biotechnologies (ADPT) is back in focus after first quarter 2026 results highlighted strong Minimal Residual Disease, or MRD, revenue trends and a higher full year MRD revenue outlook of US$260 million to US$270 million.\nSee our latest analysis for Adaptive Biotechnologies.\nThe first quarter update has come alongside a 1-month share price return of 7.15% and a year to date share price decline of 7.67%. The 1-year total shareholder return...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/a-look-at-adaptive-biotechnologies-adpt-valuation-after-stro-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/a-look-at-adaptive-biotechnologies-adpt-valuation-after-stro-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120593580","title":"Stock Track | Adaptive Biotechnologies Soars 8.85% in Pre-market on Strong Q1 Earnings Beat and Analyst Support","url":"https://stock-news.laohu8.com/highlight/detail?id=1120593580","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120593580?lang=en_us&edition=fundamental","pubTime":"2026-05-06 22:05","pubTimestamp":1778076326,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Corp's stock soared 8.85% in pre-market trading on Wednesday, following the company's better-than-expected first-quarter 2026 financial results and positive analyst...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633913826","title":"Adaptive Biotechnologies Price Target Maintained With a $22.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2633913826","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633913826?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:08","pubTimestamp":1778069280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADPT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 06, 2026 08:08 ET (12:08 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633018755","title":"J.P. Morgan Reaffirms Their Buy Rating on Adaptive Biotechnologies (ADPT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633018755","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633018755?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:20","pubTimestamp":1778066443,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Sebastian Sandler reiterated a Buy rating on Adaptive Biotechnologies today and set a price target of $19.00. According to TipR...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-reaffirms-their-buy-rating-on-adaptive-biotechnologies-adpt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-reaffirms-their-buy-rating-on-adaptive-biotechnologies-adpt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185383366","title":"Stock Track | Adaptive Biotechnologies Soars 5.30% in Night Session on Strong Q1 Earnings Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=1185383366","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185383366?lang=en_us&edition=fundamental","pubTime":"2026-05-06 12:35","pubTimestamp":1778042116,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Corp's stock soared 5.30% during night session trading on Wednesday, following the release of its first-quarter 2026 financial results.The significant price increase was...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633924785","title":"Adaptive Biotechnologies Q1 revenue beats estimates on MRD growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2633924785","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633924785?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:49","pubTimestamp":1778014193,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Q1 revenue beats estimates on MRD growthOverviewU.S. biotechnology firm's Q1 revenue rose 35% yr/yr, beating analyst expectationsQ1 adjusted EBITDA loss narrowedCompany raised","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL1N41I1C0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173247451","title":"Stock Track | Adaptive Biotechnologies Soars 16.11% After-Hours on Strong Q1 Earnings Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=1173247451","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173247451?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:49","pubTimestamp":1778014147,"startTime":"0","endTime":"0","summary":"Shares of Adaptive Biotechnologies Corp surged 16.11% in after-hours trading on Tuesday following the release of the company's first-quarter 2026 financial results.The significant price increase was...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633266449","title":"Adaptive Biotechnologies Q1 EPS $(0.13) Beats $(0.17) Estimate, Sales $70.874M Beat $60.850M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633266449","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633266449?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:09","pubTimestamp":1778011748,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 35 percent increase over losses of $(0.20) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52301964/adaptive-biotechnologies-q1-eps-0-13-beats-0-17-estimate-sales-70-874m-beat-60-850m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Adaptive Biotechnologies Q1 EPS $(0.13) Beats $(0.17) Estimate, Sales $70.874M Beat $60.850M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633692635","title":"BRIEF-Adaptive Biotechnologies Q1 EPS USD -0.13","url":"https://stock-news.laohu8.com/highlight/detail?id=2633692635","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633692635?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:05","pubTimestamp":1778011548,"startTime":"0","endTime":"0","summary":"May 05  - Adaptive Biotechnologies Q1 revenue USD 70.874 million vs. IBES estimate USD 60.9 million.Q1 adjusted EBITDA USD -2.5 million vs. IBES estimate USD -6.55 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nPLX8DB6F9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633925274","title":"Adaptive Biotechnologies Q1 Net Income USD -20.015 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633925274","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633925274?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:05","pubTimestamp":1778011505,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nPLX8DB6F9:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633212319","title":"Adaptive Biotechnologies Corp - Sees FY2026 Operating Expenses $350 Mln-$360 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2633212319","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633212319?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:05","pubTimestamp":1778011505,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nPLX8DB6F9:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633092502","title":"Adaptive Biotechnologies Q1 Adjusted Ebitda USD -2.5 Million VS. Ibes Estimate USD -6.55 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633092502","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633092502?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:05","pubTimestamp":1778011505,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nPLX8DB6F9:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156786333","title":"Stock Track | Adaptive Biotechnologies Plummets 5.03% Intraday Ahead of Q1 Earnings Report","url":"https://stock-news.laohu8.com/highlight/detail?id=1156786333","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156786333?lang=en_us&edition=fundamental","pubTime":"2026-05-05 23:47","pubTimestamp":1777996029,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Corp's stock plummeted 5.03% during intraday trading on Tuesday, as investors reacted to the company's upcoming quarterly earnings announcement.The biotechnology company is...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632934634","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2632934634","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632934634?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:00","pubTimestamp":1777888800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Adv Energy Ind                                   1Q      1.98    4:01 PM. ·Baldwin Ins Grp                                  1Q       .63    4:05 PM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALG","CRBG","DUOL","ALIT","AQST","AHCO","AVNW","AXSM","CCOI","AEIS","AGCO","ATEC","APTV","DHC","ABEV","CYRX","AMD","ALSN","BWXT","AMWL","BUD","AGBK","CRD.B","BLZE","ANDE","AEE","CSR","ADTN","CRD.A","AMRC","CRGY","APLE","BCC","ADEA","AESI","BMRN","ADCT","BDSX","BWIN","ALC","ADUS","ALKS","ADPT","DORM","ADM","ANGI","DBVT","ACEL","AOMR","AEP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632047726","title":"Assessing Adaptive Biotechnologies (ADPT) Valuation After Recent Share Price Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2632047726","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632047726?lang=en_us&edition=fundamental","pubTime":"2026-05-03 17:26","pubTimestamp":1777800375,"startTime":"0","endTime":"0","summary":"What recent performance says about Adaptive Biotechnologies\nAdaptive Biotechnologies (ADPT) has drawn fresh attention after a mixed stretch in the stock, with a slight gain over the past week, a small decline over the past month, and a sharper pullback over the past 3 months.\nSee our latest analysis for Adaptive Biotechnologies.\nAt a share price of $14.27, Adaptive Biotechnologies has had a weak stretch in recent months, with a 30 day share price return of a 3.65% decline and a 90 day share...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/assessing-adaptive-biotechnologies-adpt-valuation-after-rece-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/assessing-adaptive-biotechnologies-adpt-valuation-after-rece-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631769578","title":"Adaptive Biotech President, COO Julie Rubinstein sells 19,037 shares for $270,197.51","url":"https://stock-news.laohu8.com/highlight/detail?id=2631769578","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631769578?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:09","pubTimestamp":1777504169,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies President and COO Julie Rubinstein sold 19,037 shares on April 27, 2026 at USD 14.23.Rubinstein acquired 14,707 shares on April 27, 2026 via option exercise at USD 8.46.Directly held common stock position fell to 377,802 shares following transactions.Stock options position declined to 45,731 following exercise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL6rTn14:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotech President, COO Julie Rubinstein sells 19,037 shares for $270,197.51","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136599136","title":"Earning Preview: Adaptive Biotechnologies Corp Q1 revenue is expected to increase by 42.58%, and institutional views are cautiously bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1136599136","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136599136?lang=en_us&edition=fundamental","pubTime":"2026-04-29 02:21","pubTimestamp":1777400476,"startTime":"0","endTime":"0","summary":"Abstract Adaptive Biotechnologies Corp will release first-quarter 2026 results on May 5, 2026 Post Market; this preview summarizes consensus expectations for revenue, margins, net loss trajectory,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: Adaptive Biotechnologies Corp Q1 revenue is expected to increase by 42.58%, and institutional views are cautiously bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630735318","title":"Adaptive Biotechnologies President, COO Julie Rubinstein disposes of shares worth $802,123.4","url":"https://stock-news.laohu8.com/highlight/detail?id=2630735318","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630735318?lang=en_us&edition=fundamental","pubTime":"2026-04-25 06:30","pubTimestamp":1777069824,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies President and COO Julie Rubinstein reported sales of 57,180 shares on April 22-24 under a Rule 10b5-1 plan.Disposals were executed at weighted average prices of $14.13, $13.74, $14.02.Rubinstein also exercised stock options for 44,166 shares at $8.46 over same period.Direct ownership stood at 382,132 shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 24, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL8F3ddW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies President, COO Julie Rubinstein disposes of shares worth $802,123.4","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.adaptivebiotech.com","stockEarnings":[{"period":"1week","weight":-0.1028},{"period":"1month","weight":-0.0929},{"period":"3month","weight":-0.1783},{"period":"6month","weight":-0.0652},{"period":"1year","weight":0.458},{"period":"ytd","weight":-0.1884}],"compareEarnings":[{"period":"1week","weight":0.0227},{"period":"1month","weight":0.0773},{"period":"3month","weight":0.0974},{"period":"6month","weight":0.1135},{"period":"1year","weight":0.2733},{"period":"ytd","weight":0.0972}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.006662},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.034164},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.108302},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.084119},{"month":5,"riseRate":0.428571,"avgChangeRate":0.083655},{"month":6,"riseRate":0.833333,"avgChangeRate":0.100403},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.001043},{"month":8,"riseRate":0.571429,"avgChangeRate":0.074393},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.065733},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.030408},{"month":11,"riseRate":0.714286,"avgChangeRate":0.049327},{"month":12,"riseRate":0.714286,"avgChangeRate":0.032336}],"exchange":"NASDAQ","name":"Adaptive Biotechnologies Corp","nameEN":"Adaptive Biotechnologies Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adaptive Biotechnologies Corp(ADPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adaptive Biotechnologies Corp(ADPT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adaptive Biotechnologies Corp,ADPT,Adaptive Biotechnologies Corp股票,Adaptive Biotechnologies Corp股票老虎,Adaptive Biotechnologies Corp股票老虎国际,Adaptive Biotechnologies Corp行情,Adaptive Biotechnologies Corp股票行情,Adaptive Biotechnologies Corp股价,Adaptive Biotechnologies Corp股市,Adaptive Biotechnologies Corp股票价格,Adaptive Biotechnologies Corp股票交易,Adaptive Biotechnologies Corp股票购买,Adaptive Biotechnologies Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adaptive Biotechnologies Corp(ADPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adaptive Biotechnologies Corp(ADPT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}